[go: up one dir, main page]

WO2009118765A8 - Novel monoamine re-uptake inhibitor - Google Patents

Novel monoamine re-uptake inhibitor Download PDF

Info

Publication number
WO2009118765A8
WO2009118765A8 PCT/IN2009/000202 IN2009000202W WO2009118765A8 WO 2009118765 A8 WO2009118765 A8 WO 2009118765A8 IN 2009000202 W IN2009000202 W IN 2009000202W WO 2009118765 A8 WO2009118765 A8 WO 2009118765A8
Authority
WO
WIPO (PCT)
Prior art keywords
formula
polymorphs
prodrugs
solvates
metabolites
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2009/000202
Other languages
French (fr)
Other versions
WO2009118765A3 (en
WO2009118765A2 (en
Inventor
Satinder Vir Kessar
Shrinivas Krishnarao Kulkarni
Rajesh Jain
Sanjay Trehan
Sitaram Kumar Magadi
Jagattaran Das
Gurmeet Kaur
Kamal Nain Singh
Sneh Lata
Ashish Dhir
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panacea Biotec Ltd
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of WO2009118765A2 publication Critical patent/WO2009118765A2/en
Publication of WO2009118765A8 publication Critical patent/WO2009118765A8/en
Anticipated expiration legal-status Critical
Publication of WO2009118765A3 publication Critical patent/WO2009118765A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula (I) and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system that are responsive to inhibition of biogenic amines, in particular one or more, or any combination of serotonin, norepinephrine and dopamine.
PCT/IN2009/000202 2008-03-28 2009-03-27 Novel monoamine re-uptake inhibitor Ceased WO2009118765A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN821/DEL/2008 2008-03-28
IN821DE2008 2008-03-28

Publications (3)

Publication Number Publication Date
WO2009118765A2 WO2009118765A2 (en) 2009-10-01
WO2009118765A8 true WO2009118765A8 (en) 2010-09-10
WO2009118765A3 WO2009118765A3 (en) 2010-10-28

Family

ID=41114419

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000202 Ceased WO2009118765A2 (en) 2008-03-28 2009-03-27 Novel monoamine re-uptake inhibitor

Country Status (1)

Country Link
WO (1) WO2009118765A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5869222B2 (en) 2008-01-04 2016-02-24 インテリカイン， エルエルシー Specific chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
SG10201600179RA (en) 2011-01-10 2016-02-26 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
JP2014520776A (en) 2011-07-04 2014-08-25 バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー Use of substituted isoquinolinones, isoquinoline diones, isoquinoline triones and dihydroisoquinolinones or their salts in each case as active agents against abiotic stresses in plants
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
HUE040126T2 (en) 2012-11-01 2019-02-28 Infinity Pharmaceuticals Inc Treatment of cancers using modulators of PI3 kinase isoform
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
CN106686980B (en) * 2014-09-19 2019-09-24 株式会社可乐丽 The biological corrosion inhibitor of metal
CN106995410B (en) * 2016-01-26 2021-03-02 江苏恩华药业股份有限公司 Lactam derivative and application thereof
UA125216C2 (en) 2016-06-24 2022-02-02 Інфініті Фармасьютікалз, Інк. COMBINED THERAPY

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2853649B1 (en) * 2003-04-09 2006-07-14 Servier Lab NOVEL ISOQUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
RU2388751C2 (en) * 2004-07-15 2010-05-10 Амр Текнолоджи, Инк. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof for inhibiting norepinephrine, dopamine and serotonin reuptake
WO2007072041A1 (en) * 2005-12-23 2007-06-28 Astex Therapeutics Limited Therapeutic compounds

Also Published As

Publication number Publication date
WO2009118765A3 (en) 2010-10-28
WO2009118765A2 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
WO2009118765A3 (en) Novel monoamine re-uptake inhibitor
MX2009012685A (en) Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors.
WO2007081857A3 (en) Cycloalkylamines as monoamine reuptake inhibitors
WO2009093269A9 (en) Novel heterocyclic compounds
WO2012042539A3 (en) 3 -azabicyclo [3.1.0] hexane compounds useful for the treatment of cns disorders
WO2010150281A3 (en) Novel azabicyclohexanes
MX2008013583A (en) Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them.
WO2013038429A3 (en) Novel sglt inhibitors
NO20080981L (en) Nitrocatechol derivatives as COMT inhibitors
MY158339A (en) DIAMIDE COMPOUNDS HAVING MUSCARING RECEPTOR ANTAGONIST AND ß2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
MX368368B (en) Indole and indazole compounds as an inhibitor of cellular necrosis.
WO2010088050A3 (en) Bicyclic pyrazolo-heterocycles
MY146924A (en) Substituted imidazoheterocycles
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
WO2008060621A3 (en) Aminopyrrolidines as chemokine receptor antagonists
BRPI0612072A2 (en) aspartyl protease inhibitors
MX353209B (en) D2 ANTAGONISTS, METHODS OF SYNTHESIS and METHODS OF USE.
HK1206021A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
WO2008130879A3 (en) Tetrahydroindole and tetrahydroindazole derivatives
WO2010043953A3 (en) Novel bridged cyclic compounds as histone deacetylase inhibitors
GEP20135806B (en) Lactams as beta secretase inhibitors
MX2011013507A (en) Novel gpr 119 agonists.
WO2012172566A3 (en) Novel sglt inhibitors
WO2010011811A3 (en) 3-(phenoxyphenylmethyl)pyrrolidine compounds
EA201270421A1 (en) 1,2-DIHYDRO-2-OXOHINOLINE COMPOUNDS AS LIGANDS OF 5-NT RECEPTOR

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09725049

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 09725049

Country of ref document: EP

Kind code of ref document: A2